DBV Technologies.
publicly owned French biopharmaceutical firm headquartered in Bagneux, France
DBV Submits FDA Application for Peanut Allergy Patch in Young Children
DBV Technologies has filed for FDA approval of its VIASKIN peanut-allergy patch for children ages 4 to 7 and requested Priority Review. The application is supported by a successful Phase 3 trial involving 654 children; the patch delivers small amounts of peanut protein through the skin to gradually desensitize patients.
Business · 10 sources · 1dRead itThe journal
Open the journal →The conversation starts in the journal — be the first to post.
About DBV Technologies
DBV Technologies SA is a publicly owned French biopharmaceutical firm headquartered in Bagneux, France. DBV Technologies is known for developing "Viaskin" technology for administering allergens or antigens to intact skin while avoiding any transfer to the blood. Viaskin Peanut clinical development has received Fast Track designation from the US Food and Drug Administration.
Everything about DBV Technologies →- Country
- France
- Headquarters
- Bagneux
- Inception
- March 29, 2002, 2002
- Website
- http://www.dbv-technologies.com/